{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/alopecia-androgenetic-male/prescribing-information/finasteride/","result":{"pageContext":{"chapter":{"id":"c42ae7ac-8352-5cac-874c-69c24b99081b","slug":"finasteride","fullItemName":"Finasteride","depth":2,"htmlHeader":"<!-- begin field 6ce8387d-5853-4fdc-b29e-f6d82ecf86b4 --><h2>Finasteride</h2><!-- end field 6ce8387d-5853-4fdc-b29e-f6d82ecf86b4 -->","summary":"","htmlStringContent":"<!-- begin item 19fa2c33-dc64-421c-91e9-4d479700635d --><!-- begin field 21bd37e9-85fd-4873-8ee6-bbb722307b6d --><ul><li>Finasteride 1 mg tablets (Propecia®) are not available to prescribe on the NHS, but can be prescribed on a private prescription.</li><li>Finasteride 1 mg tablets are a prescription-only medicine and cannot be purchased over-the-counter. However, in some areas, they are available to purchase from a pharmacy under local Patient Group Directive (PGD) arrangements.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">BNF 71, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">NHS Business Services Authority, 2016</a>]</p><!-- end field 21bd37e9-85fd-4873-8ee6-bbb722307b6d --><!-- end item 19fa2c33-dc64-421c-91e9-4d479700635d -->","topic":{"id":"5f58d6a9-7ba5-59ad-b7d6-e461768e2621","topicId":"c4dc3303-ee1d-42aa-8da5-078adb684e06","topicName":"Alopecia, androgenetic - male","slug":"alopecia-androgenetic-male","lastRevised":"Last revised in July 2018","chapters":[{"id":"e3fc5b8b-475e-5a1f-a596-104fbf00064f","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"c40b9d81-bd18-5ef2-8284-4c4e6005d65c","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"d860e13e-49f1-54f2-872f-2f3439f27003","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"bbc072f8-3fd9-5a1c-b94c-a0e4fd6edc2f","slug":"changes","fullItemName":"Changes"},{"id":"746928be-2acf-5ae9-9f81-02a942d56a15","slug":"update","fullItemName":"Update"}]},{"id":"3f6cf011-8136-5f24-8cce-31a439cce866","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"5e802365-89ef-5f47-a758-6c880bb456ac","slug":"goals","fullItemName":"Goals"},{"id":"9ed869e3-e3ae-56e1-ae20-0a46d6e20fa2","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"d90f156b-7429-5580-b4c3-e50d840d1c8a","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c879d8ad-590c-56af-9685-9eb9a2e30d54","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"9e4f37dc-4cc8-5e88-a803-5ca32ca17da9","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"5df134be-2105-5321-86a8-71ed6dca8ebb","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"8a3725c2-b01f-5dd8-a319-33387b40d0ee","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"762358f6-f003-57e8-97ff-1c81299e9364","slug":"definition","fullItemName":"Definition"},{"id":"9ee0c90d-fd96-523f-8f6f-7a26ec56b9c7","slug":"prognosis","fullItemName":"Prognosis"},{"id":"55784b07-7a42-5c0b-9ff3-e9c83216cb1e","slug":"complications","fullItemName":"Complications"},{"id":"7cde82a5-0086-5e04-a669-ec49787685f0","slug":"prevalence","fullItemName":"Prevalence"},{"id":"33fac4d7-a95d-526c-936a-6983e3a12d95","slug":"causes","fullItemName":"Causes"},{"id":"84f86e20-aa91-5e2b-b0b6-bb3cfbf655d6","slug":"risk-factors","fullItemName":"Risk factors"}]},{"id":"4b1bf49e-974e-517b-abd6-59b7ea701502","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"486adc7a-b20b-584e-b20c-1408c8f2dc42","slug":"diagnosis-assessment","fullItemName":"Diagnosis and assessment"},{"id":"afbd97db-7525-51a6-aafe-6e937f1cc3e1","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"4fa73515-d20e-5178-9d6b-eebf5ae2d527","slug":"investigations","fullItemName":"Investigations"}]},{"id":"622bcbbb-d3de-5b15-9b55-ddc4eff327ab","fullItemName":"Management","slug":"management","subChapters":[{"id":"18247780-bdd9-5da4-9d33-1bcf2a883881","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"37e93d68-3a6a-5889-a376-afa236d390aa","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"baab0697-37a1-5edf-88ac-cfb6e2e5656b","slug":"topical-minoxidil-2percent-5percent","fullItemName":"Topical minoxidil 2% and 5%"},{"id":"c42ae7ac-8352-5cac-874c-69c24b99081b","slug":"finasteride","fullItemName":"Finasteride"}]},{"id":"b22c3dba-eb5b-5afa-8f70-43908da7e430","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"444a2a47-2816-5baa-928f-c2bc1b56af85","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"1d1c173f-70b1-5d42-916a-a0bcb5c3557c","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"531d7be1-4263-5fd6-a49b-a920a3aaca95","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"dede1c7c-59ec-550c-be37-91849715881e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ddffa446-a263-56e2-a985-c07fa5d06760","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"3b6f4b5d-c7dd-5142-a6e8-2741d9019ade","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"0b9ed9ca-1edc-5d61-938a-a6abc5daa77a","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"37e93d68-3a6a-5889-a376-afa236d390aa","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"fb11e0fd-91c9-5aa9-8880-48cac3ce9c35","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 14751262-7919-4784-b889-2b7a7d1fbee3 --><h3>What are the contraindications and cautions for finasteride?</h3><!-- end field 14751262-7919-4784-b889-2b7a7d1fbee3 -->","summary":"","htmlStringContent":"<!-- begin item 3e671948-39d6-49f1-9086-1f440f9f4f1a --><!-- begin field 242bde9a-5595-4b05-ba24-59bb8411db16 --><ul><li><strong>Finasteride should be avoided in men who:</strong><ul><li>Are hypersensitive to finasteride.</li><li>Have severe liver disease.</li></ul></li><li><strong>Finasteride should be used with caution in men who:</strong><ul><li>Have mild to moderate liver disease.</li><li>Have obstructive uropathy.</li><li>Have a female partner.<ul><li>Women of childbearing potential whose male partner is taking oral finasteride, should avoid handling crushed or broken tablets of finasteride due to the risk in pregnancy (including abnormalities of the external genitalia of a male fetus). </li><li>Although finasteride is excreted in semen, there is no need for a man to use a condom if his sexual partner is pregnant or likely to become pregnant, as the amount of finasteride excreted following a 1 mg dose is too small to be harmful.</li></ul></li><li>Need prostate-specific antigen (PSA) monitoring — to interpret a PSA level in a man treated with finasteride for 6 months or more, consider doubling the PSA result, as finasteride may decrease serum PSA levels.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">ABPI Medicines Compendium, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">BNF 71, 2016</a>]</p><!-- end field 242bde9a-5595-4b05-ba24-59bb8411db16 --><!-- end item 3e671948-39d6-49f1-9086-1f440f9f4f1a -->","subChapters":[]},{"id":"3f61fbf0-03c1-5eed-8c86-ca1bbb3446fa","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field b97640f5-664d-431b-8b28-f1c0c1d37a38 --><h3>What are the adverse effects of finasteride?</h3><!-- end field b97640f5-664d-431b-8b28-f1c0c1d37a38 -->","summary":"","htmlStringContent":"<!-- begin item 0d7eb1c9-408e-42f3-b397-31f15bfa2771 --><!-- begin field 45ba3fd6-724b-42ab-a625-e4cf289f5378 --><ul><li>Finasteride is generally well tolerated.</li><li>Sexual problems are the most common adverse effects which tend to occur during the first year of treatment, but decrease with duration of treatment, and usually resolve when the medication is discontinued [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">Mysore and Shashikumar, 2016</a>]. Sexual adverse effects persisting after discontinuation of finasteride 1mg have been reported rarely [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">Belknap et al, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">Irwig, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">Mysore and Shashikumar, 2016</a>].</li><li>Prescribers should discuss with men, the potential for sexual adverse effects with finasteride 1 mg daily which include:<ul><li>Decreased libido (which occurs in about 1–2% of men).</li><li>Erectile dysfunction (which occurs in about 1–1.5% of men).</li><li>Ejaculation disorders (such as decreased volume of ejaculate).</li></ul></li><li>Other adverse effects include:<ul><li>Hypersensitivity reactions (such as lip and face swelling, itch and rash).</li><li>Testicular pain.</li><li>Haematospermia.</li><li>Breast tenderness and enlargement.<ul><li>Advise men taking finasteride to promptly report to their doctor any changes in their breast tissue (such as lumps, pain, or nipple discharge).</li><li>The Medicines and Healthcare products Regulatory Agency (MHRA) has reported three cases of breast cancer in men taking finasteride 1 mg. Overall incidence is not increased but in view of these reports, a connection cannot be excluded.</li></ul></li></ul></li><li>Depression, anxiety and suicidal thoughts with treatment have been observed. Men are advised to stop therapy if they develop depression.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">ABPI Medicines Compendium, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">BNF 71, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">MHRA, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">ABPI, 2018</a>]</p><!-- end field 45ba3fd6-724b-42ab-a625-e4cf289f5378 --><!-- end item 0d7eb1c9-408e-42f3-b397-31f15bfa2771 -->","subChapters":[]},{"id":"ff938a1d-0e0a-568f-91f0-624663904ac0","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 1a1fe1ca-cd6d-4f97-8490-951548651fa4 --><h3>What are the drug interactions of finasteride?</h3><!-- end field 1a1fe1ca-cd6d-4f97-8490-951548651fa4 -->","summary":"","htmlStringContent":"<!-- begin item 7565a442-004a-4ade-9df4-898eae6005ec --><!-- begin field 2e05e7ca-2319-41fc-9d27-30bceef8bc41 --><ul><li>There are no clinically significant drug interactions with finasteride.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">ABPI Medicines Compendium, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">BNF 71, 2016</a>]</p><!-- end field 2e05e7ca-2319-41fc-9d27-30bceef8bc41 --><!-- end item 7565a442-004a-4ade-9df4-898eae6005ec -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}